A Study of Survival and Outcome After Stroke (SOS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. The target population is a stroke cohort with a known infarct volume who presents within 8 hours from symptom onset with a NIH Stroke Scale (NIHSS) score >10 who are eligible for mechanical thrombectomy but without receiving the treatment. Functional outcome as defined by the modified Rankin Scale (mRS) of all enrolled patients will be followed for 90 days after the index event.
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The SOS Study: A Study of Survival and Outcome After Stroke |
- Proportion of patients with a modified Rankin score of 2 or less [ Time Frame: 90 days after the procedure ] [ Designated as safety issue: No ]
- NIHSS score of 0-1 or a 10 or more points improvement [ Time Frame: Discharge ] [ Designated as safety issue: No ]
- All cause mortality [ Time Frame: 90 days post-procedure ] [ Designated as safety issue: Yes ]
- Incidents of symptomatic and asymptomatic intracranial hemorrhage [ Time Frame: 90 days post-procedure ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 150 |
| Study Start Date: | September 2010 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Standard of Care
Standard of Care for stroke except mechanical therapy
|
Detailed Description:
The objective of this observational study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. The target population is a stroke cohort with a known infarct volume who presents within 8 hours from symptom onset with a NIH Stroke Scale (NIHSS) score >10. Functional outcome as defined by the modified Rankin Scale (mRS) of all enrolled patients will be followed for 90 days after the index event. This is a prospective, single arm, multi-center trial. Up to 200 patients at up to 30 centers will be enrolled in the study. It is anticipated that up to 150 evaluable patients will be needed for analysis. The sample size estimate is based on the primary study functional outcome at 90 days as defined by a mRS of 0-2. Assuming that this observational study will have as outcome of 25% (37/150) mRS 0-2 at day 90, the expected two-sided exact binomial confidence interval is (18%, 32%). This sample size is adequate to estimate the mRS outcome of 0-2 at day 90 for the natural history of acute ischemic stroke.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset and with an imaging-defined large cerebral vessel occlusion and a known infarct volume will be enrolled and followed for 90-days.
Inclusion Criteria:
- From 18 to 85 years of age
- Evidence of proximal anterior circulation large vessel occlusion (TIMI 0-1/TICI 0-1)from CT Angiography. Target vessel occlusion may include the supra-clinoid segment of the ICA through the M1 segment of the MCA.
- Presented with symptoms consistent with acute ischemic stroke within 8 hours of symptom onset. Patients who presented within 3 hours must be ineligible or refractory to IV rtPA therapy.
- At time of enrollment, neurological deficit resulting in an NIH Stroke Scale (NIHSS) score > 10
- Known core infarct volume assessed by CTP, CTA or DWI scans
Exclusion Criteria:
- History of stroke in the past 3 months.
- Pre-existing neurological or psychiatric disease that could confound the study results such as a pre-stroke mRS score >1
- Known severe allergy to contrast media
- Uncontrolled hypertension (defined as systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg)
CT evidence of the following conditions before enrollment:
- Significant mass effect with midline shift
- Evidence of intracranial hemorrhage
- Treated with endovascular therapy for acute stroke
- Life expectancy was thought to be less than 90 days prior to stroke due to non-stroke illness
- Participation in another clinical investigation that could confound the evaluation of the study
Contacts and Locations| Contact: Siu P Sit, PhD | 510 748 3200 ext 221 | siupo.sit@penumbrainc.com |
| United Kingdom | |
| Acute Vascular Imaging Centre, John Radcliffe Hospital, University of Oxford | Recruiting |
| Oxford, United Kingdom, OX3 9DU | |
| Contact: Iris Q Grunwald, MD PhD 0044 1865 234688 I.grunwald@gmx.net | |
| Principal Investigator: Iris Q Grunwald, MD PhD | |
| Principal Investigator: | Iris Q Grunwald, MD | The John Radcliffe Hospital, Oxford, UK |
More Information
No publications provided
| Responsible Party: | Siu Po Sit, VP, Clinical Affairs, Penumbra Inc. |
| ClinicalTrials.gov Identifier: | NCT01193569 History of Changes |
| Other Study ID Numbers: | CLP2818, CLP2818 |
| Study First Received: | August 31, 2010 |
| Last Updated: | December 10, 2012 |
| Health Authority: | Oxford Radcliffe Hospitals National Health Service Trust:United Kingdom |
Additional relevant MeSH terms:
|
Stroke Cerebral Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases Brain Infarction Brain Ischemia |
ClinicalTrials.gov processed this record on May 16, 2013